To raise money at $1 considering the last round was at the same price in this market is magnificent! I reckon you would be hard to have not lost 30% of your capital if you had it spread across 10 other biotechs in the last year...
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
